Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

CARDIOVASCULAR DISEASE DIAGNOSTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following two broad segments – In Vitro Diagnostics, and In Vivo Diagnostics. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomérieux, Cambridge Heart, Inc., Cholestech Corp., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc., Ortho-Clinical Diagnostics, Inc., Philips Healthcare, Polymer Technology Systems, Inc., Response Biomedical Corp., Roche Diagnostics, Siemens Healthcare Diagnostics, Inc., St. Jude Medical, Inc., and EP MedSystems. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1096
Price : $4500
Companies : 71
Pages : 477
Date : February 2011
Market Data Tables : 80

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  CARDIOVASCULAR DISEASE DIAGNOSTICS (Complete Report) Pages : 477   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......13 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2  
   Data Interpretation & Reporting Level.......3
Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
In Vitro Diagnostics.......3
In Vivo Diagnostics.......3
  
  2. INDUSTRY OVERVIEW.......56 $595  
   Cardiovascular Diseases: The Undying Challenge.......5 1$100
   Table 1: Region-Wise Incidence and Prevalence of Cardiovascular Diseases in 2006.......6
Mounting Healthcare Costs - Calls for Early Diagnosis.......6
Cardiovascular Disease Diagnostics: Playing a Pivotal Role in Early Disease
  Detection.......6
1$300
   Developed Countries Dominate, Developing to be the Future Growth Engine.......7
Fast and Accurate Diagnosis – Reduce Unnecessary Healthcare Costs.......7
1$100
   POC Diagnostics Market Gains Momentum.......8
Cardiac Markers - Making Diagnosis Easier and Quicker.......8
1$100
   Major Cardiac Markers and their Properties.......9
What’s New in POC Cardiac Markers Space?.......9
1$100
   Leading Players.......10
List of Point of Care Cardiac Marker Testing Products.......10
1$100
  3. IN-VIVO DIAGNOSTICS.......114 $495  
   Table 2: Global In-vivo Cardiovascular Disease Diagnostics Market by Region: 2010 (includes corresponding Graph/Chart).......11
Novel Imaging Techniques Boost In vivo Diagnostics Market.......11
1$300
   Non-Invasive Procedure Hogs the Limelight for Cardiovascular Treatment.......12
Cardiology Diagnostic Imaging.......12
New Technologies Bring Diagnostics Closer to Patients.......12
1$100
   Trends Cited in the Imaging Technologies Market.......13
CT Scanners.......13
1$100
   MRI.......14
Move Towards Efficient Patient Data Management.......14
1$100
  4. IN-VITRO DIAGNOSTICS.......156 $950  
   A Quick Insight into the Global In-vitro Diagnostics Market.......15
Growth Trends.......15
Developed Countries Drive In-Vitro Diagnostics (IVD) Market.......15
1$100
   Table 3: Leading In-Vitro Diagnostics Markets Worldwide (2007): Percentage Breakdown for North America, Europe, Japan, and Others (includes corresponding Graph/Chart).......16
Established Players Dominate the Fragmented Market.......16
Table 4: Leading Players in the Global In-Vitro Diagnostics Market (2009): Percentage Breakdown of Value Sales for Roche Diagnostics, Abbott Diagnostics, Ortho/ LifeScan, Bayer/Siemens, Beckman Coulter, BD, Dade Behring, bioMerieux and Others (includes corresponding Graph/Chart).......16
1$300
   Point-of-Care In-Vitro Testing on the Roll.......17
Table 5: Global In vitro Diagnostics Market by Type of Test (2007): Percentage Breakdown for Central Lab Testing, Point-of-Care Testing, and Molecular Testing (includes corresponding Graph/Chart).......17
A Specific Focus on Global Cardiovascular In-Vitro Diagnostics Market.......17
1$300
   Market Analysis.......18
Table 6: World Cardiovascular In-vitro Diagnostics Market: 2010 (includes corresponding Graph/Chart).......18
Aging Population Drives Home Testing Market.......18
1$300
   Cholesterol and Other Cardiovascular Test Kits Offered by Leading Companies.......19
Development of Home Cholesterol Testing Kits.......19
Table 7: Global Cholesterol Point-of-Care Rapid Tests Market (2009): Market Shares of Leading Players by Value Sales for Inverness Medical, Roche, Abaxis, and Others (includes corresponding Graph/Chart).......19
Strong Demand for Risk Assessment Markers.......19
1$300
   Advancements in Alternate-Site Coagulation Monitoring.......201$100
  5. CVD - CAUSE AND RISK FACTORS.......217 $950  
   CVD - Global Facts.......21
Table 8: CVD Death Rates (per 100,000 population) Among Men (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart).......21
1$300
   Table 9: CVD Death Rates (per 100,000 population) Among Women (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart).......22
Atherosclerosis - Leading Cause for CVD.......22
Risk Factors.......22
Irreversible Risk Factors.......22
Increasing age.......22
1$300
   Sex (gender).......23
Heredity (including Race).......23
Risk Factors that can be controlled.......23
Tobacco Smoke.......23
High Blood Cholesterol.......23
1$100
   LDL Cholesterol.......24
HDL Cholesterol.......24
Triglyceride levels.......24
1$100
   Hypercholesterolemia - Conditions Associated with Cholesterol Level.......25
High Blood Pressure.......25
1$100
   BP - Leading Cause of Cardiovascular Disease in Young Adults.......26
Physical Inactivity.......26
Obesity and Overweight.......26
Diabetes Mellitus.......26
Cardiovascular Disease and Homocysteine Levels.......26
1$100
   Measures for Reducing Cardiovascular Diseases.......271$100
  6. CARDIOVASCULAR DISEASE AND CONDITIONS.......283 $395  
   Angina Pectoris.......28
Arrhythmias.......28
Sudden Cardiac Death (SCD).......28
Stroke.......28
1$100
   Congestive Heart Failure.......29
Heart Failure Classification as per the NYHA and ACC/AHA.......29
1$100
   Table 10: Prevalence Rates of Congestive Heart Failure in Select Countries (per 10,000) (includes corresponding Graph/Chart).......30
Cardiovascular Disease Involving Transplant Patients.......30
1$300
  7. DIAGNOSTIC TESTS FOR CARDIOVASCULAR DISEASES.......3112 $950  
   In-Vitro Cardiovascular Diagnostics.......31
Cholesterol Testing.......31
Use of Markers.......31
Creatine Kinase MB.......31
1$100
   Troponin T and Troponin I.......32
C-Reactive Protein.......32
1$100
   Plasminogen Activator Inhibitor-1.......33
D-Dimer.......33
Thrombus Precursor Protein.......33
Other Cardiac Markers.......33
Increasing Popularity of Risk Assessment Markers.......33
1$100
   A Step Forward in Cardiovascular Risk Assessment.......34
In Vivo Diagnostic Tests.......34
Computed Imaging / Tomography.......34
Electron Beam Computed Tomography (EBCT).......34
1$100
   Appropriate Conditions for EBCT Diagnosis.......35
Cardiac Positron Emission Tomography (PET).......35
1$100
   Digital Cardiac Angiography/ Digital Subtraction Angiography.......36
Magnetic Resonance Imaging (MRI).......36
1$100
   Single Photon Emission Computed Tomography (SPECT).......37
Echocardiography.......37
Different Types of Echo-techniques.......37
M-mode (Motion mode, One-dimensional).......37
1$100
   Two-Dimensional (Cross-sectional).......38
Stress Echocardiogram (Stress Echo).......38
Transesophageal Echocardiogram (TEE).......38
Risks.......38
Ultrasound Tests.......38
Doppler Ultrasound.......38
1$100
   Intravascular Ultrasound.......39
Working.......39
Comparative Facts Related to Definitive Diagnosis of Cardiovascular Disease.......39
1$100
   Nuclear Cardiology Tests.......40
Applications.......40
Types of Nuclear Cardiology Tests.......40
Myocardial Perfusion Imaging.......40
1$100
   Applications.......41
Risks.......41
Ventricular Function Test.......41
1$100
   Testing Cardiac Stress.......42
Cardio Vascular Disease Diagnostics Tests in the Pipeline.......42
Aderis MRE-0470.......42
CardioMEMS Novel Technology.......42
Technology Platform.......42
1$100
  8. PRODUCT LAUNCHES AND DEVELOPMENTS.......436 $495  
   Cardiac Science Launches Microvolt T-Wave Alternans Module.......43
Cleveland HeartLab to Extend Test Menu.......43
St. Jude Medical Introduces EnSite Derexi Module.......43
1$100
   NorDiag Unveils NorDiags Arrow Instrument.......44
Biosense Webster Launches CARTO® 3 System.......44
McKesson Unveils New Variant of Horizon Cardiology Cardiovascular Information
  System.......44
Correlagen Launches CardioGeneScan Test.......44
1$100
   Royal Philips Electronics to Launch PageWriter TC50 Cardiograph.......45
Philips Introduces Xcelera R3.1.......45
St. Jude Medical Launches Medical Devices for Heart Rhythms Disorders.......45
1$100
   TomTec and Medis Launches Cardiac Imaging and Analysis Product.......46
Royal Philips Electronics Launches PageWriter TC70.......46
1$100
   Philips Healthcare to Introduce CX50 CompactXtreme.......47
Royal Philips Electronics Introduces Xcelera R2.2.......47
Toshiba America to Launch AplioTM Artida.......47
2$200
  9. PRODUCT LAUNCHES AND DEVELOPMENTS IN THE RECENT PAST - A PERSPECTIVE
  BUILDER.......49
18 $1450  
   Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner.......49
Royal Philips Launches Live 3D Transesophageal Echocardiogram Probe.......49
GE Healthcare Launches Vivid e Ultrasound Systems.......49
Cardionetics Launches ECG Monitor for 24-Hour Real-Time Cardiac Diagnosis.......49
1$100
   Siemens Launches Imaging Release for the ACUSON Sequoia Platform.......50
GE Healthcare Launches Version 2.0 of Centricity Cardiology CA1000.......50
GE Healthcare Introduces New Capabilities to CardioSoft Diagnostic Software.......50
GE Healthcare’s Lightspeed VCT Offers Imaging at 70% Lower Exposure.......50
1$100
   Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker System (Outside
  US).......51
Royal Philips Launches New Imaging Tool for Complex Cardiac Arrhythmias.......51
Siemens Medical Introduces syngo® US, New Echocardiography Solution........51
Dade Behring Introduces CardioPhase® hsCRP Test for Multiple Testing
  Platforms........51
1$100
   Shimadzu Launches Two Models in Angiographic Imaging.......52
Omron Healthcare Introduces Non Invasive Vascular Profiling System.......52
Abbott Launches XIENCE V, New Coronary Stent System.......52
Siemens Medical Introduces Acuson AcuNav 8F, an Advanced Ultrasound Catheter .......52
1$100
   BioMérieux Introduces High Performance VIDAS Troponin I Ultra.......53
Siemens Launches Acuson X300 Ultrasound Platform.......53
Siemens Releases Web-Enabled CT.......53
1$100
   GE Introduces Latest Electrocardiograph Device, MAC 3500.......54
GE Emphasizes on the Striking Features of New Vivid 7 Dimension ’06.......54
GE Launches Latest Innova Digital Flat Panel Biplane Imaging Devices.......54
1$100
   Medtronic Introduces Latest Range of Implantable Cardiac Defibrillators.......55
Philips Introduces Web Based Cardiac Tools.......55
Siemens Showcases Solutions for Cardiac Problems Through Molecular Imaging.......55
Siemens Presents Advancements in Echocardiography.......55
1$100
   Siemens Debuts syngo BEAT.......56
Siemens Combines syngo® Dynamics with Soarian® for Cardiovascular EPR.......56
GE Healthcare Unveils CardIQ Fusion.......56
GE Introduces Discovery VCT.......56
GE Unveils Dynamic VUE.......56
1$100
   GE Launches CardIQ Xpress.......57
GE Presents the Ventri for Cardiac Imaging.......57
GE Introduces High Definition Magnetic Resonance System.......57
Dade Behring Unveils CardioPhase(R) hsCRP Test.......57
Siemens Launches Encompass III on C512 Ultrasound Platform.......57
1$100
   Siemens Launches Four New CT Clinical Engines.......58
Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool.......58
Corgenix Introduces Predictive Cardiovascular Diagnostic Kit, AtherOx™.......58
Philips Introduces HD11 XE Cardiology Ultrasound System.......58
1$100
   Siemens Introduces Biplane FD Cardiology System.......59
Siemens Introduces Syngo Circulation Software for CT Tomography.......59
Siemens Introduces SOMATOM Definition for Cardiac Imaging.......59
Dade Behring Unveils Homocysteine Test on BN (TM) Systems.......59
Roche Unveils Cardiac pro-BNP Test.......59
1$100
   Philips Introduces HD11 XE.......60
Corgenix Unveils AtherOx(TM).......60
GE Healthcare Unveils Breakthrough Imaging Technology.......60
Philips Launches Products to Detect Heart Problems.......60
1$100
   Philips Unveils Computed Tomography and EP Planning package.......61
Philips Widens Magnetic Resonance Portfolio.......61
New Cardiac Monitoring Products from Philips.......61
Siemens Launches Image-Arena.......61
Siemens Announces New Procam-Calculator Combined with CT Examination.......61
1$100
   Siemens Medical Solutions Launches Axiom Artis dTA.......62
GE Healthcare Unveils Vivid i.......62
1$100
   GE Healthcare Presents Fully Integrated 4D Cardiovascular Ultrasound System.......63
GE Healthcare Debuts New Imaging System.......63
New Discovery PET/CT Systems from GE Healthcare.......63
SonoSite Presents SonoCalc IMT Software.......63
1$100
   Dade Behring Introduces High Sensitivity Troponin I Assay.......64
Biosite Unveils New Diagnostic Test.......64
MDS Diagnostic Services Unveils New Test to Prevent Heart Disease.......64
1$100
   diaDexus Develops PLAC Test.......65
Siemens Introduces New Nuclear Cardiology Imaging System.......65
Roche Diagnostics Receives U.S. Clearance and European CE Mark.......65
1$100
   Camtronics Unveils Cardiovascular Screening Software.......66
Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment Test.......66
1$100
  10. RECENT INDUSTRY ACTIVITY.......679 $595  
   Inverness Changes Name to Alere.......67
Miraculins Acquires PreMD’s PREVU(i) Skin Cholesterol Test Assets.......67
Kardia Health Systems Partners with TomTec Imaging Systems.......67
TriLink and Biofortuna Ink Licensing Agreement.......67
1$100
   Corgenix Enters into a Strategic Alliance with ELITech.......68
VaxGen to Merge with diaDexus.......68
St. Jude Medical to Take Over LightLab Imaging.......68
1$100
   GE Healthcare and CardioDx Enter into Strategic Alliance.......69
bioMerieux and Knome Ink Strategic Partnership Agreement.......69
Merge Healthcare Acquires AMICAS.......69
1$100
   Diamedix and Nova Ink Distribution Agreement.......70
Inverness Acquires Standard Diagnostics.......70
Quidel Acquires Diagnostic Hybrids.......70
bioMérieux Acquires Meikang Biotech.......70
1$100
   Aurora Health Care Partners with Celera.......71
Mediscience Technology Corporation Acquires SensiVida Medical Systems.......71
Volcano Acquires Axsun Technologies.......71
Thermo Fisher Takes Over B.R.A.H.M.S........71
1$100
   SonoSite Acquires CardioDynamics International.......72
IntriCon Snaps Up Datrix.......72
ST. Jude Medical Receives US FDA and European Approval for EnSite Velocity™ Cardiac
  Mapping System.......72
Roche Inks Agreement with Response Biomedical.......72
1$100
   Dynatek Dalta Scientific Inks Agreement with State Food and Drug
  Administration.......73
Amic Inks Licensing Deal with Roche Diagnostics.......73
TRICARE Includes Atherotech’s VAP® Test.......73
1$100
   PreMD Receives NSE Letter from US FDA for POC Skin Cholesterol Test.......74
Amic Gains License for Roche’s Cardiac Marker.......74
diaDexus and Fisher HealthCare Sign Agreement.......74
1$100
   Inverness Inks Distribution Agreement with PrognostiX.......75
GE Healthcare Enters into Collaboration with Boston Scientific.......75
St. Jude Medical Acquires EP MedSystems.......75
1$100
  11. INDUSTRY ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER.......7616 $950  
   Inverness Takes Over Biosite.......76
Siemens Medical Acquires Dade Behring.......76
Inverness Medical Innovations Acquires Cholestech.......76
1$100
   Acrongenomics, Pearson and Molecular Enter into Joint Venture.......77
Cholestech Teams Up with Onsite Health Diagnostics.......77
Lipomics to Collaborate with Agilent Technologies to Develop Diagnostic Tests........77
1$100
   Transgenomic and Fiuotecnica Renew Collaboration Agreement.......78
Alteon and BioRap Technologies Enter into an Agreement.......78
IM Medical Acquires New Technology for Detecting Cardiovascular Diseases.......78
Medtronic Establishes New Business Entity.......78
1$100
   Siemens Medical Acquires Bayer Healthcare’s Diagnostics Unit.......79
Inverness Medical Innovations Completes Acquisition of HemoSense.......79
Spacelabs Acquires Ferraris’ Cardiac Unit.......79
1$100
   Global Immune Takes over Primedical International.......80
Siemens Acquires Diagnostics Products.......80
Cholestech and Life Line Enter into Collaboration.......80
LipoScience Signs an Agreement with ARUP.......80
Philips Acquires Witt Biomedical.......80
1$100
   CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray.......81
Biosense Enters into Strategic Partnership with Siemens Medical Solutions.......81
Dade Behring Approved the Use of FSAP Antibodies by American Diagnostica.......81
Abbott Receives Non-exclusive Sublicense for Diagnostic Use of PIGF.......81
1$100
   Nanogen Acquires Spectral’s Cardiac Test Division.......82
Varian Enters into Alliance with LipoScience to Jointly Develop NMR System.......82
Cardiac Services Professionals Establish eCardio Diagnostics.......82
1$100
   Response Biomedical Wins Nonexclusive License Rights for NT-proBNP and Troponin
  T.......83
Biomerieux gains Nonexclusive License for NT-proBNP.......83
Philips and PMI Ink an Agreement for Outpatient Facility.......83
LipoScience Enters into an Agreement with LabCorp.......83
Abbott and Cleveland Clinic to Co-develop Myeloperoxidase Cardiac Test.......83
1$100
   Abbott Receives 510(k) Clearance from FDA for Myoglobin Test.......84
FDA Clears Additional Claim for Biosite’s Triage (R) BNP Test.......84
Biosite Inks an Agreement with University of Mainz.......84
Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay.......84
Nanogen Acquires SYN•X Pharma.......84
1$100
   GE Takes Over Amersham Plc.......85
St. Jude Medical Acquires Irvine Biomedical and Epicor.......85
SonoSite Snaps Up SonoMetric.......85
CardioDynamics Acquires Vermed.......85
Philips and EP MedSystems Announce an Alliance Involving Electrophysiology
  Solutions.......85
Toshiba and ViTAL Enters into an Alliance with Johns Hopkins University School of
  Medicine.......85
1$100
   Response Biomedical Collaborates with Shionogi.......86
Terumo Signs Agreement with Spencer Technologies.......86
Spectral Diagnostics Announces Agreement with NGC Medical.......86
Philips Signs Agreement with Fletcher Allen Health Care.......86
Spectral Diagnostics Enters into an Agreement with Cardinal Health.......86
Siemens Signs Agreement with MediGuide.......86
1$100
   Biosite Enters into Agreement with DMI BioSciences.......87
Cambridge Heart Enters into Agreement with Del Mar Reynolds.......87
Cholestech Enters into an Agreement with Itamar Medical.......87
Siemens Enters into a Contract with HiPGraphics.......87
1$100
   Abbott Announces US Clearance for Axis-Shield’s BNP Test for Use on AxSYM.......88
Cholestech Announces FDA 510(k) Approval for hs-CRP Test.......88
Dade Behring Bags FDA Clearance NT-proBNP Test.......88
Dade Behring Receives FDA Clearance for N High Sensitivity CRP Assay.......88
EP-4 Computerized Cardiac Stimulator Bags FDA Approval.......88
Biosite Adds two new offices.......88
1$100
   Bayer Diagnostics Enhances BNP Assay Offering Globally.......89
EP MedSystems Garners CE Approval for ALERT Deflectable CS Catheter in Europe.......89
Cambridge Heart Inc. and Quinton Cardiology Systems Renew Pact.......89
1$100
   EPIX and Schering AG Extends Collaboration Agreement.......90
Siemens Ultrasound and TomTec Imaging Systems Announces Agreement.......90
FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative Cardiovascular
  Devices.......90
Beckman Coulter Enters into Agreement with Biosite.......90
1$100
   Dade Behring Garners Non-exclusive Rights for a Key Cardiac Marker.......91
Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc to Develop
  CardioGen-82®.......91
New Lab Test from diaDexus Receives FDA Clearance.......91
Hypertension Diagnostics Receives SDA Approval in China.......91
1$100
  12. FOCUS ON SELECT GLOBAL PLAYERS.......9210 $595  
   AccuTech, LLC (USA).......92
Abbott Diagnostics (USA).......92
Alere Inc. (USA).......92
2$200
   Biosite, Inc. (USA).......94
Ani Biotech Oy (Finland).......94
Axis-Shield PoC (UK).......94
1$100
   Beckman Coulter, Inc. (USA).......95
biomérieux (France).......95
Cambridge Heart, Inc. (USA).......95
1$100
   Cholestech Corp. (USA).......96
GE HealthCare (UK).......96
1$100
   Home Access Health Corporation (USA).......97
LifeSign LLC (USA).......97
Liposcience, Inc. (USA).......97
1$100
   Nanosphere, Inc. (USA).......98
Ortho-Clinical Diagnostics, Inc. (USA).......98
Philips Healthcare (USA).......98
1$100
   Polymer Technology Systems, Inc. (USA).......99
Response Biomedical Corp. (Canada).......99
1$100
   Roche Diagnostics (Switzerland).......100
Siemens Healthcare Diagnostics, Inc. (USA).......100
1$100
   St. Jude Medical, Inc. (USA).......101
EP MedSystems (USA).......101
1$100
  13. GLOBAL MARKET PERSPECTIVE.......102   
   Table 11: World Recent Past, Current & Future Market Analysis for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1021$300
   Table 12: World Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East, and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1031$300
   Table 13: World 11-Year Perspective for Cardiovascular Disease Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1041$300
   Table 14: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1051$300
   Table 15: World Historic Review for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1061$300
   Table 16: World 11-Year Perspective for Cardiovascular In Vitro Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1071$300
   Table 17: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1081$300
   Table 18: World Historic Review for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1091$300
   Table 19: World 11-Year Perspective for Cardiovascular In Vivo Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1101$300
  14. THE UNITED STATES.......11112 $2450  
   A. Market Analysis.......111
Trends and Issues.......111
Innovations Drive the Usage of Cardiovascular Monitoring Systems.......111
Cholesterol POCT Market: An Overview.......111
1$100
   Table 20: US Cholesterol Point-of-Care Testing (2009): Market Shares of Leading Players by Value Sales for Inverness Medical, Polymer Technology Systems, and Roche Diagnostics (includes corresponding Graph/Chart).......112
Increasing Cardiovascular Ailments Drive Sales of Home Test Devices.......112
CHF Biomarkers to Spearhead the US market.......112
1$300
   Table 21: US AMI (Acute Myocardial Infarction) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).......113

Table 22: US CHF (Congestive Heart Failure) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).......113
Cardiovascular Disease Prevalence in the US.......113
1$300
   Key Statistics on Cardiovascular Diseases.......114
Mortality Statistics.......114
1$100
   Table 23: Prevalence of Cardiovascular Disease in the US (2004): A Historic Review (includes corresponding Graph/Chart).......115

Table 24: Percentage Breakdown of Deaths from Cardiovascular Diseases in the US (2004): A Historic Review (includes corresponding Graph/Chart).......115
1$300
   Table 25: Prevalence of Cardiovascular Diseases among Americans by Age (Age 20 and Older) and Sex (2004): A Historic Review (includes corresponding Graph/Chart).......116

Table 26: A Factoid of CHD and MI (In Million) in the US (2003): A Historic Review.......116
Startling facts related to Stroke in US.......116
1$300
   Table 27: A Factoid of Stroke (In Million) in the US (2003): A Historic Review.......117
Incidence of Coronary Heart Disease.......117
AHA Statistics for Coronary Heart Disease.......117
1$300
   Mortality rates of CHD.......118
Table 28: Annual Number of Americans Having Diagnosed Heart Attack by Age and Sex (2004) (includes corresponding Graph/Chart).......118
1$300
   Table 29: Prevalence of CHD by Age and Sex (2004) (In % population) (includes corresponding Graph/Chart).......119
Arrhythmias.......119
CAD Diagnostics.......119
1$300
   PVD Diagnostics.......120
Medicare Reimbursement Set for CPT Code 83704.......120
Competitive Glance.......120
Point-of-Care (POC) Diagnostics Market in the US.......120
1$100
   Table 30: Leading Players in the US POC Cardiac Market (2004) - Percentage Breakdown by Value Sales for Biosite, Dade Behring, Spectral Diagnostics, Roche and Others (includes corresponding Graph/Chart).......121
B. Market Analytics.......121
Table 31: US Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......121
1$300
   Table 32: US Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......122

Table 33: US 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......122
1$300
  15. CANADA.......1232 $595  
   A. Market Analysis.......123
Cardiovascular Disease Facts.......123
B. Market Analytics.......123
Table 34: Canadian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......123
1$300
   Table 35: Canadian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......124

Table 36: Canadian 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......124
1$300
  16. JAPAN.......1252 $595  
   Market Analysis.......125
Table 37: Japanese Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......125
1$300
   Table 38: Japanese Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......126

Table 39: Japanese 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......126
1$300
  17. EUROPE.......1277 $1450  
   A. Market Analysis.......127
In Vivo Diagnostics – Major Segment in CVD Diagnostics Market.......127
Germany - The Largest European Market.......127
Cardiovascular Disease – Mortality Statistics.......127
1$100
   Table 40: Leading Cause of Death Among Men in Europe (2007): Percentage Breakdown for Cardiovascular Diseases, Poisoning and Injuries, Respiratory Disease, Cancer, and Others (includes corresponding Graph/Chart).......128

Table 41: Leading Cause of Death Among Women in Europe (2007): Percentage Breakdown for Cardiovascular Diseases, Poisoning and Injuries, Respiratory Disease, Cancer, and Others (includes corresponding Graph/Chart).......128
Cardiovascular Disease – Risk Factor Profile.......128
1$300
   The Cardiovascular Disease Cost Burden.......129
B. Market Analytics.......129
Table 42: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......129
1$300
   Table 43: European Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1301$300
   Table 44: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1311$300
   Table 45: European Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1321$300
   Table 46: European 11-Year Perspective for Cardiovascular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).......133

Table 47: European 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......133
1$300
  17a. FRANCE.......1342 $595  
   Market Analysis.......134
Table 48: French Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......134
1$300
   Table 49: French Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......135

Table 50: French 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......135
1$300
  17b. GERMANY.......1362 $595  
   Market Analysis.......136
Table 51: German Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......136
1$300
   Table 52: German Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......137

Table 53: German 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......137
1$300
  17c. ITALY.......1382 $595  
   Market Analysis.......138
Table 54: Italian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......138
1$300
   Table 55: Italian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......139

Table 56: Italian 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......139
1$300
  17d. THE UNITED KINGDOM.......1403 $595  
   A. Market Analysis.......140
UK Cardiovascular Diseases Fact Sheet.......140
1$100
   B. Market Analytics.......141
Table 57: UK Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......141
1$300
   Table 58: UK Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......142

Table 59: UK 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......142
1$300
  17e. SPAIN.......1432 $595  
   Market Analysis.......143
Table 60: Spanish Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......143
1$300
   Table 61: Spanish Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......144

Table 62: Spanish 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......144
1$300
  17f. RUSSIA.......1453 $595  
   A. Market Analysis.......145
Major Players.......145
1$100
   B. Market Analytics.......146
Table 63: Russian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......146
1$300
   Table 64: Russian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......147

Table 65: Russian 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......147
1$300
  17g. REST OF EUROPE.......1482 $595  
   Market Analysis.......148
Table 66: Rest of Europe Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......148
1$300
   Table 67: Rest of Europe Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......149

Table 68: Rest of Europe 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......149
1$300
  18. ASIA PACIFIC.......1505 $950  
   A. Market Analysis.......150
Cardiovascular Market in Asia-Pacific.......150
China.......150
Healthcare Expenditure to Grow Considerably by 2015.......150
1$100
   In vitro Diagnostics Market Poised for Strong Growth.......151
Domestic Manufacturers Pose a Threat for Overseas IVD Manufacturers.......151
Leading Players.......151
Cardiovascular Disease Patients Overview.......151
1$100
   Treatment Providers and Hospitals Overview.......152
Hospitals.......152
Table 69: Cardiovascular Special Treatment Hospitals in China: 1991-2011(In numbers) (includes corresponding Graph/Chart).......152
Chinese Cardiovascular Disease Treatment as a Part of Overall Health Care
  Industry.......152
1$300
   Table 70: Cardiovascular Disease Treatment in China: 1991-2006 (includes corresponding Graph/Chart).......153
B. Market Analytics.......153
Table 71: Asia-Pacific Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......153
1$300
   Table 72: Asia-Pacific Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......154

Table 73: Asia-Pacific 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......154
1$300
  19. THE MIDDLE EAST.......1552 $595  
   Market Analysis.......155
Table 74: The Middle East Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).......155
1$300
   Table 75: The Middle East Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......156

Table 76: The Middle East 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......156
1$300
  20. LATIN AMERICA.......1573 $595  
   A. Market Analysis.......157
Brazil: A Growing Market for IVD.......157
Table 77: Brazilian IVD Market by Segment (2009): Percentage Share Breakdown for Immunoassay, Hormone, Microbiology, Biochemistry, Hematology, Molecular Diagnostics, Cardiac markers, Hemostasis, and Cytology (includes corresponding Graph/Chart).......157
1$300
   B. Market Analytics.......158
Table 78: Latin American Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......158
1$300
   Table 79: Latin American Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......159

Table 80: Latin American 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2010 & 2015.......159
1$300
COMPETITION 305$995
  
Total Companies Profiled: 71 (including Divisions/Subsidiaries - 82)

Region/Country                 Players


The United States                 57    
Canada                             3
Japan                              4
Europe                            15 
     France                        1
     Germany                       1
     The United Kingdom            5
     Italy                         3
     Rest of Europe                5
Asia-Pacific (Excluding Japan)     1
Middle-East                        2
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign